Acadia Healthcare Company, Inc. (ACHC) 2023 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning and welcome to the Acadia Healthcare Third Quarter 2023 Earnings Conference Call. (Operator Instructions) Please also note that this event is being recorded today.

    早安,歡迎參加 Acadia Healthcare 2023 年第三季財報電話會議。(接線員指示)另請注意,本活動今日將進行錄音。

  • I would now like to turn the conference over to Gretchen Hommrich. Please go ahead.

    現在我想將會議交給 Gretchen Hommrich。請開始。

  • Gretchen Hommrich - VP of IR

    Gretchen Hommrich - VP of IR

  • Good morning, and welcome to Acadia's Third Quarter 2023 Conference Call. I'm Gretchen Hommrich, Vice President of Investor Relations for Acadia. Here with me today are Chris Hunter, Acadia's Chief Executive Officer; and Heather Dixon, our Chief Financial Officer.

    早安,歡迎參加 Acadia 2023 年第三季電話會議。我是 Gretchen Hommrich,Acadia 投資人關係副總裁。今天與我一同出席的有 Acadia 執行長 Chris Hunter,以及我們的財務長 Heather Dixon。

  • I'll first provide you with our safe harbor before turning the call over to Chris. To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link. This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements among others, regarding Acadia's expected quarterly and annual financial performance for 2023 and beyond.

    在把電話交給 Chris 之前,我先提供我們的安全港聲明。若今日電話會議中討論任何非 GAAP 財務衡量指標,您也可在我們網站上,透過「投資人」連結查看昨日新聞稿,找到該衡量指標與依 GAAP 計算之最直接可比財務衡量指標的調節表。本電話會議可能包含《1995 年私人證券訴訟改革法》所定義的前瞻性陳述,其中包括但不限於關於 Acadia 對 2023 年及其後預期的季度與年度財務表現之陳述。

  • You are hereby cautioned that these statements may be affected by the important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's third quarter news release and consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements.

    特此提醒您,這些陳述可能會受到多項重要因素影響(其中包括但不限於)Acadia 向美國證券交易委員會提交之文件以及公司第三季新聞稿中所列因素;因此,實際營運與結果可能與前瞻性陳述中討論的結果存在重大差異。

  • At this time, I would like to turn the conference call over to our Chief Executive Officer, Chris Hunter, for opening remarks.

    此時,我想將電話會議交給我們的執行長 Chris Hunter 發表開場致詞。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Thank you, Gretchen, and good morning, everyone. Thank you for being with us for Acadia's Third Quarter 2023 Conference Call. Before we discuss the results, I want to note an important recent addition to Acadia's leadership. Last week, we announced that Dr. Patrice Harris has been appointed to the company's Board of Directors. Dr. Harris is a Board-certified in psychiatry and has diverse experience as a Private Practicing Physician, Public Health Director and Patient Advocate. She served as President of the American Medical Association from 2019 to 2020, where she was the first African-American woman to be elected to this prestigious position.

    謝謝你,Gretchen,各位早安。感謝各位參加 Acadia 2023 年第三季電話會議。在討論業績之前,我想提及近期 Acadia 領導團隊一項重要新增成員。上週我們宣布,Patrice Harris 醫師已獲任命為公司董事會成員。Harris 醫師為精神醫學專科醫師,並具備多元經驗,曾任私人執業醫師、公共衛生主管及病患倡議者。她於 2019 至 2020 年擔任美國醫學會(AMA)會長,並成為首位當選此一崇高職位的非裔美國女性。

  • She also served as Chair of the AMA's opioid task force and on AMA work groups devoted to health information technology, sustainable growth rate and private contracting. She continues to work in private practice and as Chief Executive Officer of eMed Digital Healthcare, a digital healthcare company she cofounded.

    她亦曾擔任 AMA 鴉片類藥物工作小組主席,並參與 AMA 多個工作小組,專注於健康資訊科技、可持續成長率(SGR)以及私人合約等議題。她目前仍持續從事私人執業,並擔任 eMed Digital Healthcare 的執行長;該公司為她共同創辦的數位醫療公司。

  • Dr. Harris brings deep clinical expertise in areas that are core to Acadia's mission and we look forward to her valuable insights as we continue to execute our growth strategy.

    Harris 醫師在與 Acadia 使命核心相關的領域具備深厚臨床專業,我們期待在持續推進成長策略的同時,能獲得她寶貴的洞見。

  • Now turning to the results. For the third quarter, we delivered strong financial and operating performance as we continue to see growing demand for our behavioral health services across our 4 distinct lines of business. With solid execution on our core business combined with sustained execution of our strategy, we are consistently able to meet this demand as well as deliver on our key performance objectives.

    接著談到業績。第三季我們交出強勁的財務與營運表現,並持續看到我們四大不同業務線的行為健康服務需求成長。憑藉對核心業務的扎實執行,以及對策略的持續落實,我們一貫能滿足此需求,同時達成關鍵績效目標。

  • Top and bottom line growth this quarter was impressive. We reported year-over-year revenue growth of 12.5%, adjusted EBITDA growth of 13.4% and adjusted EPS growth of 13.8% excluding income from the provider relief fund recognized in the third quarters of 2023 and 2022. Notably, our same-facility revenue increased 13% compared with the third quarter last year with the increase driven by both volume and rate improvements.

    本季營收與獲利端的成長令人印象深刻。若排除 2023 年與 2022 年第三季認列之提供者救助基金(provider relief fund)收入,我們年增營收 12.5%、調整後 EBITDA 年增 13.4%,以及調整後 EPS 年增 13.8%。值得注意的是,我們同店營收較去年第三季成長 13%,成長動能同時來自量與價的改善。

  • Similar to what we've experienced throughout 2023, these third quarter results reflect the collective impact of the ongoing focus on our core business and our progress against our growth strategy. In addition to our core financial metrics, we were pleased to see further sequential improvement in our labor trends with 2023 wage inflation decreasing from 7.5% in the first quarter to 6.3% in the second quarter to 5.7% in the third quarter, an improvement of 180 basis points so far this year.

    與我們在 2023 年迄今的經驗一致,第三季結果反映了我們持續聚焦核心業務以及推進成長策略所帶來的綜合影響。除核心財務指標外,我們也樂見人力趨勢進一步連續改善:2023 年薪資通膨由第一季的 7.5% 降至第二季的 6.3%,再降至第三季的 5.7%,今年迄今改善 180 個基點。

  • Additionally, recent investments to focus on employee engagement have supported our ability to attract and retain employees in a competitive market. Our most recent employee survey showed notable improvement in engagement. In addition, attrition rates across a number of our clinical positions have declined. We expect further improvement in this trend as we remain focused on employee engagement and continue to share best practices across our 253 facilities.

    此外,近期針對員工敬業度的投資,支持我們在競爭激烈的市場中吸引並留任員工。我們最新的員工調查顯示敬業度有顯著提升。同時,多個臨床職位的離職率亦已下降。隨著我們持續聚焦員工敬業度,並在 253 家機構間分享最佳實務,我們預期此趨勢將進一步改善。

  • Our team has done an outstanding job in effectively managing our operations as we experienced higher volumes in our current facilities and added more capacity through the continued delivery of our 5 defined growth pathways. In support of our first pathway, facility expansions, we have added 204 beds to existing facilities through the first 9 months of the year.

    在現有機構量能提升、就診量增加之際,我們的團隊在有效管理營運方面表現出色,並透過持續推進我們所定義的五大成長途徑來增加更多產能。就第一項途徑「機構擴建」而言,今年前九個月我們已在既有機構新增 204 張病床。

  • Thank you, Gretchen, and good morning, everyone. Thank you for being with us for Acadia's Third Quarter 2023 Conference Call. Before we discuss the results, I want to note an important recent addition to Acadia's leadership. Last week, we announced that Dr. Patrice Harris has been appointed to the company's Board of Directors. Dr. Harris is a Board-certified in psychiatry and has diverse experience as a private practicing physician, public health Director and patient advocate. She served as President of the American Medical Association from 2019 to 2020, where she was the first African-American woman to be elected to this prestigious position. She also served as Chair of the AMA's opioid task force and on AMA work groups devoted to health information technology, sustainable growth rate and private contracting. She continues to work in private practice and as Chief Executive Officer of eMed Digital Healthcare, a digital healthcare company she cofounded.

    謝謝你,Gretchen,各位早安。感謝各位參加 Acadia 2023 年第三季電話會議。在討論業績之前,我想提及近期 Acadia 領導團隊一項重要新增成員。上週我們宣布,Patrice Harris 醫師已獲任命為公司董事會成員。Harris 醫師為精神醫學專科醫師,並具備多元經驗,曾任私人執業醫師、公共衛生主管及病患倡議者。她於 2019 至 2020 年擔任美國醫學會(AMA)會長,並成為首位當選此一崇高職位的非裔美國女性。她亦曾擔任 AMA 鴉片類藥物工作小組主席,並參與 AMA 多個工作小組,專注於健康資訊科技、可持續成長率(SGR)以及私人合約等議題。她目前仍持續從事私人執業,並擔任 eMed Digital Healthcare 的執行長;該公司為她共同創辦的數位醫療公司。

  • Dr. Harris brings deep clinical expertise in areas that are core to Acadia's mission, and we look forward to her valuable insights as we continue to execute our growth strategy.

    Harris 醫師在與 Acadia 使命核心相關的領域具備深厚臨床專業,我們期待在持續推進成長策略的同時,能獲得她寶貴的洞見。

  • Now turning to the results. For the third quarter, we delivered strong financial and operating performance as we continue to see growing demand for our behavioral health services across our 4 distinct lines of business. With solid execution on our core business, combined with sustained execution of our strategy, we are consistently able to meet this demand as well as deliver on our key performance objectives.

    接著談到業績。第三季我們交出強勁的財務與營運表現,並持續看到我們四大不同業務線的行為健康服務需求成長。憑藉對核心業務的扎實執行,並結合對策略的持續落實,我們一貫能滿足此需求,同時達成關鍵績效目標。

  • Top and bottom line growth this quarter was impressive. We reported year-over-year revenue growth of 12.5%, adjusted EBITDA growth of 13.4% and adjusted EPS growth of 13.8%, excluding income from the provider relief fund recognized in the third quarters of 2023 and 2022. Notably, our same-facility revenue increased 13% compared with the third quarter last year, with the increase driven by both volume and rate improvements.

    本季營收與獲利端的成長令人印象深刻。若排除 2023 年與 2022 年第三季認列之提供者救助基金(provider relief fund)收入,我們年增營收 12.5%、調整後 EBITDA 年增 13.4%,以及調整後 EPS 年增 13.8%。值得注意的是,我們同店營收較去年第三季成長 13%,成長動能同時來自量與價的改善。

  • Similar to what we've experienced throughout 2023, these third quarter results reflect the collective impact of the ongoing focus on our core business and our progress against our growth strategy. In addition to our core financial metrics, we were pleased to see further sequential improvement in our labor trends with 2023 wage inflation decreasing from 7.5% in the first quarter to 6.3% in the second quarter to 5.7% in the third quarter, an improvement of 180 basis points so far this year.

    與我們在 2023 年迄今的經驗一致,第三季結果反映了我們持續聚焦核心業務以及推進成長策略所帶來的綜合影響。除核心財務指標外,我們也樂見人力趨勢進一步連續改善:2023 年薪資通膨由第一季的 7.5% 降至第二季的 6.3%,再降至第三季的 5.7%,今年迄今改善 180 個基點。

  • Additionally, recent investments to focus on employee engagement have supported our ability to attract and retain employees in a competitive market. Our most recent employee survey showed notable improvement in engagement. In addition, attrition rates across a number of our clinical positions have declined. We expect further improvement in this trend as we remain focused on employee engagement and continue to share best practices across our 253 facilities.

    此外,近期針對員工敬業度的投資,支持我們在競爭激烈的市場中吸引並留任員工。我們最新的員工調查顯示敬業度有顯著提升。同時,多個臨床職位的離職率亦已下降。隨著我們持續聚焦員工敬業度,並在 253 家機構間分享最佳實務,我們預期此趨勢將進一步改善。

  • Our team has done an outstanding job in effectively managing our operations as we experienced higher volumes in our current facilities and added more capacity through the continued delivery of our 5 defined growth pathways. In support of our first pathway, facility expansions, we have added 204 beds to existing facilities through the first 9 months of the year. We are on track to meet our objective to add a total of approximately 300 beds to existing facilities in 2023.

    在現有機構量能提升、就診量增加之際,我們的團隊在有效管理營運方面表現出色,並透過持續推進我們所定義的五大成長途徑來增加更多產能。就第一項途徑「機構擴建」而言,今年前九個月我們已在既有機構新增 204 張病床。我們正按計畫達成 2023 年在既有機構合計新增約 300 張病床的目標。

  • For our second pathway, we remain focused on developing wholly owned de novo facilities in underserved markets for Behavioral Healthcare Services. To this end, we're making good progress on opening a newly renovated 101-bed adult hospital in outpatient facility, which is part of the Montrose Behavioral Health Hospital in Chicago, Illinois as well as an 80-bed inpatient hospital, Coachella Valley Behavioral Health in Indio, California. Both are expected to open by the end of this year.

    就我們的第二條成長路徑而言,我們仍專注於在行為醫療服務資源不足的市場,開發由我們全資擁有的全新(de novo)設施。為此,我們在推進兩個項目方面進展良好:其一是在伊利諾伊州芝加哥的 Montrose Behavioral Health Hospital 旗下,一座新整修的 101 床成人醫院門診設施;其二是在加州印第奧(Indio)的 80 床住院醫院 Coachella Valley Behavioral Health。兩者預計都將於今年年底前開業。

  • Our CTC service line continues to expand its industry-leading position with 155 locations across 32 states and a flexible suite of service of solutions from traditional OTPs to mobile vans and telehealth solutions. We opened 2 new CTC locations in the third quarter, making a total of 4 CTCs opened so far this year. We're on track to open 6 CTCs in 2023 and are focused on accelerating our growth in the future.

    我們的 CTC 服務線持續擴大其業界領先地位,在 32 個州共設有 155 個據點,並提供彈性的服務與解決方案組合,涵蓋傳統 OTP 到行動車與遠距醫療解決方案。我們在第三季新開設 2 個 CTC 據點,使今年迄今新開設的 CTC 總數達到 4 個。我們正按計畫於 2023 年開設 6 個 CTC,並專注於在未來加速成長。

  • Importantly, the need for our services has never been greater. More than 9 million Americans are suffering from opioid use disorder. And just last year, the country witnessed approximately 110,000 overdose deaths, tragically a record high.

    重要的是,對我們服務的需求從未如此迫切。超過 900 萬名美國人正受阿片類藥物使用障礙所苦。僅在去年,全國約出現 11 萬起藥物過量死亡,令人痛心地創下歷史新高。

  • Regarding our third growth pathway, we are especially proud of the expanded scale of care we can deliver to communities across the country through relationships with renowned joint venture partners. Early in the third quarter, we opened a 96 bed hospital with our joint venture partner, Bronson Healthcare in Battle Creek, Michigan and another 96 bed hospital with our partner Geisinger in Moosic, Pennsylvania. This is the first of 2 hospitals we will be opening with Geisinger in the state. We anticipate breaking ground in early 2024 on the second hospital in Danville, Pennsylvania.

    關於我們第三條成長路徑,我們特別以能透過與知名合資夥伴的合作關係,將可提供的照護規模擴大至全國各地社區而感到自豪。第三季初,我們與合資夥伴 Bronson Healthcare 在密西根州巴特爾克里克(Battle Creek)開設了一家 96 床醫院,並與夥伴 Geisinger 在賓夕法尼亞州穆西克(Moosic)開設了另一家 96 床醫院。這是我們將在該州與 Geisinger 開設的兩家醫院中的第一家。我們預期將於 2024 年初在賓夕法尼亞州丹維爾(Danville)的第二家醫院動工。

  • We are also pleased to highlight that this week, we broke ground on our previously announced Behavioral Health Hospital with joint venture partner, ECU Health, Eastern North Carolina's Premier Health System. This new hospital will expand our acute service line into the North Carolina market and will serve as a destination academic site, training students and residents from the ECU's Brody School of Medicine.

    我們也很高興強調,本週我們已為先前宣布、與合資夥伴 ECU Health(東北卡羅來納州首屈一指的醫療體系)合作的行為健康醫院舉行動土典禮。這家新醫院將把我們的急性照護服務線擴展至北卡羅來納州市場,並將作為目的地型的學術基地,培訓來自 ECU Brody 醫學院的學生與住院醫師。

  • We look forward to working together with these Premier Health Systems to provide quality behavioral healthcare in their respective markets. With our clinical expertise and standing as the leading pure-play provider of Behavioral Healthcare Services, Acadia remains an attractive partner for health systems who want to expand behavioral healthcare treatment options in their respective communities.

    我們期待與這些頂尖醫療體系攜手合作,在其各自市場提供高品質的行為醫療照護。憑藉我們的臨床專業,以及作為行為醫療服務領域領先的純粹型(pure-play)供應商之地位,Acadia 仍是希望在其社區擴大行為醫療治療選項之醫療體系的具吸引力合作夥伴。

  • Working together, we have a shared commitment to provide access to quality care and support the critical need in the community. Today, Acadia's 20 joint venture partnerships represent a combined total of 21 hospitals with 11 hospitals already in operation and 10 hospitals expected to open over the next several years.

    透過共同合作,我們秉持一致承諾:提供高品質照護的可近性,並支援社區的迫切需求。目前,Acadia 的 20 項合資合作關係合計代表 21 家醫院,其中 11 家已投入營運,另有 10 家預計將在未來數年內開業。

  • In addition, we recently broke ground on a second hospital with an existing JV partner, which we will announce in the next several months. This will be our second partnership with 2 hospitals in different markets demonstrating the value of these collaborations to both our partners and to us. The pipeline for potential partners remains robust and joint ventures will continue to play an important role in Acadia's future growth.

    此外,我們近期也與既有的合資夥伴為第二家醫院動土,並將在未來幾個月內對外宣布。這將是我們第二個「在不同市場擁有兩家醫院」的合作關係,展現此類合作對夥伴與我們雙方的價值。潛在合作夥伴的管線仍然強勁,合資模式將持續在 Acadia 未來成長中扮演重要角色。

  • With respect to our fourth growth pathway, we are focusing on identifying acquisitions that support our growth objectives and meet the criteria of our capital allocation strategy. During the third quarter, we announced a definitive agreement to acquire Turning Point Centers, a specialty provider of substance use disorder and primary mental health treatment services that cares for patients in the Salt Lake City, Utah metropolitan market. This acquisition will allow us to operate the 76 beds in their current facilities and over time, add an additional 48 beds to the operations. We expect to close this transaction by the end of 2023.

    就我們第四條成長路徑而言,我們專注於辨識能支持成長目標、並符合資本配置策略標準的併購案。第三季,我們宣布已簽署最終協議,將收購 Turning Point Centers——一家專精於物質使用障礙與主要心理健康治療服務的供應商,服務範圍涵蓋猶他州鹽湖城都會市場的病患。此項收購將使我們得以營運其現有設施中的 76 床,並隨時間推進再新增 48 床。我們預期將於 2023 年底前完成此交易。

  • As you know, extending the continuum of care is our fifth and final growth pathway. One of the key focus areas of this pathway is expanding partial hospitalization programs or PHP and Intensive Outpatient Programs or IOP, that can provide 4 to 6 hours of care per day.

    如各位所知,延伸照護連續體是我們第五條也是最後一條成長路徑。此路徑的關鍵重點之一,是擴大部分住院計畫(PHP)與密集門診計畫(IOP),其可每日提供 4 至 6 小時的照護。

  • We believe the impact of PHP IOP on the clinical outcomes of our patients can be significant for multiple reasons.

    我們相信,PHP/IOP 對病患臨床結果的影響可能相當顯著,原因有多方面。

  • First, the vast majority of our acute and specialty patients are indicated for PHP IOP as a step-down therapy post discharge as they transition back to the community. Second, PHP IOP has a strong record of positively affecting post-discharge health outcomes. And lastly, we believe there's a clinical opportunity for a larger share of our patients to access and appropriately utilize PHP IOP. To support this goal, we will continue to expand our PHP IOP offerings across facilities, including 3 new programs in the third quarter and 26 programs through the first 9 months of the year.

    首先,我們絕大多數的急性與專科病患,在出院後回歸社區的過渡期,適合以 PHP/IOP 作為降階(step-down)治療。其次,PHP/IOP 在改善出院後健康結果方面有良好紀錄。最後,我們認為在臨床上仍有機會讓更大比例的病患取得並適切使用 PHP/IOP。為支持此目標,我們將持續在各設施擴增 PHP/IOP 供給,包括第三季新增 3 個新方案,以及今年前 9 個月合計新增 26 個方案。

  • Through each of these 5 growth pathways, we are well positioned to maintain our growth trajectory and meet our stated development targets for calendar '23 as follows: adding 670 beds through approximately 300 bed additions to existing facilities, of which already -- we've already added 204 beds year-to-date; opening 2 inpatient de novo hospitals, Montrose Behavioral Health Hospital and Coachella Valley Behavioral Health, which we expect to complete by year-end; opening 2 hospitals with JV partners, which we completed early in the third quarter; and then opening 6 CTC locations, of which we have already opened for this year.

    透過這 5 條成長路徑,我們已具備良好條件以維持成長軌跡,並達成我們對 2023 年曆年所提出的開發目標如下:新增 670 床,其中約 300 床來自既有設施的擴床,而我們年初至今已新增 204 床;開設 2 家全新(de novo)住院醫院——Montrose Behavioral Health Hospital 與 Coachella Valley Behavioral Health——我們預期將於年底前完成;與合資夥伴開設 2 家醫院,我們已於第三季初完成;以及開設 6 個 CTC 據點,其中今年我們已開設 4 個。

  • Looking ahead to 2024, we have significant opportunities for further growth through our defined pathways and consistent with what we shared in our first ever Investor Day a year ago at Carnegie Hall in New York. With respect to our joint ventures, we look forward to continued progress into 2024 with projects that are already underway. We would like to preview a few highlights.

    展望 2024 年,透過我們所定義的成長路徑,我們仍有顯著的進一步成長機會,這也與我們一年前在紐約卡內基音樂廳首次投資人日所分享的內容一致。就合資案而言,我們期待 2024 年持續推進已在進行中的專案。我們想先預告幾項重點。

  • First, together with our partner, Henry Ford Health, one of the nation's premier academic and integrated health systems, we will open a 192 bed joint venture inpatient Behavioral Health Hospital serving the Metro-Detroit area. Second, together with one of the premier health systems in Colorado, Intermountain Health, we will open a 144-bed inpatient Behavioral Health Hospital, which will serve Denver area residents. This hospital will expand our acute service line into Colorado.

    第一,我們將與夥伴 Henry Ford Health(全美首屈一指的學術型與整合型醫療體系之一)共同開設一所 192 床的合資住院行為健康醫院,服務底特律都會區。第二,我們將與科羅拉多州的頂尖醫療體系之一 Intermountain Health 共同開設一所 144 床的住院行為健康醫院,服務丹佛地區居民。該院將把我們的急性照護服務線擴展至科羅拉多州。

  • And as previously mentioned, we expect to announce a second hospital with an existing joint venture partner in the next several months, which has already begun construction. We expect these facilities to open in 2024.

    此外,如先前所提,我們預期在未來幾個月內宣布與既有合資夥伴合作的第二家醫院,該項目已開始施工。我們預期這些設施將於 2024 年開業。

  • In addition to these JV facilities, we have several de novo facilities that will begin to care for patients in 2024 as well. As we previously announced, we plan to open a 100-bed acute Behavioral Health Hospital in Mesa, Arizona, Agave Ridge Behavioral Health.

    除上述合資設施外,我們也有數個全新(de novo)設施將於 2024 年開始收治病患。如我們先前宣布,我們計畫在亞利桑那州梅薩(Mesa)開設一所 100 床的急性行為健康醫院 Agave Ridge Behavioral Health。

  • Additionally, we recently acquired a building on 10 acres of land that will allow us to expand our specialty services in Florida. This convertible facility near Tampa expected to open its first 20 beds in the second quarter of 2024 and includes plans to expand this facility to 80 beds in the future. This specialty facility will treat patients recovering from substance use disorders.

    另外,我們近期收購了一棟位於 10 英畝土地上的建物,使我們得以在佛羅里達州擴展專科服務。這座位於坦帕附近、可改造的設施,預計於 2024 年第二季先開放首批 20 床,並規劃未來將該設施擴增至 80 床。此專科設施將治療正在從物質使用障礙中復原的病患。

  • And finally, we'd like to highlight our new acute care Behavioral Health Facility in Madison, Wisconsin. While Acadia has a presence in the state with our 14 CTCs in the specialty SUD residential treatment program, our 120-bed acute care hospital represents an important new market entry for Acadia's acute de novo growth.

    最後,我們也想重點介紹位於威斯康辛州麥迪遜(Madison)的新急性照護行為健康設施。雖然 Acadia 透過在該州設立的 14 個 CTC,以及專科 SUD 住宿式治療計畫已具備據點,但我們這家 120 床的急性照護醫院,代表 Acadia 在急性全新(de novo)成長方面進入重要新市場。

  • As we continue to extend our market reach, safety and quality care remain our top priorities in every aspect of patient care. We're committed to implementing the right training and leadership development along with the right technology to ensure we're delivering the best possible outcomes for our patients. We have made significant technology investments this year to deliver strong clinical outcomes and further drive efficiencies in our business. Our recent investments in electronic medical records and patient monitoring technology are yielding early benefits and support our medical teams with respect to patient safety and compliance.

    隨著我們持續擴大市場觸及範圍,安全與高品質照護仍是病患照護各面向的首要優先事項。我們致力於導入適當的訓練與領導力發展,以及合適的科技,以確保為病患帶來最佳可能的結果。今年我們已進行重大科技投資,以實現強勁的臨床結果並進一步提升營運效率。我們近期在電子病歷與病患監測技術上的投資已開始帶來初步效益,並在病患安全與法規遵循方面支援我們的醫療團隊。

  • We are extremely proud of the work that we are doing and our progress to date in 2023. Across the company, our dedicated employees and clinicians are addressing the nation's critical need for safe quality treatment for mental health and substance use issues. We are well positioned to leverage our scale and expertise and continue to reach more patients and their families who desperately need our help.

    我們對於2023年迄今所做的工作以及取得的進展感到無比自豪。在全公司範圍內,我們敬業的員工與臨床人員正回應全國對安全且高品質之心理健康與物質使用問題治療的迫切需求。我們已具備良好條件,可運用我們的規模與專業能力,持續觸及更多迫切需要我們協助的病患及其家屬。

  • At this time, I will now turn the call over to Heather to discuss our financial results for the quarter and 2023 guidance.

    此時,我將把電話會議交給Heather,請她說明本季的財務結果以及2023年指引。

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Thanks, Chris, and good morning, everyone. Our third quarter financial performance reflects the continued favorable growth in our business in 2023.

    謝謝你,Chris,各位早安。我們第三季的財務表現反映出2023年我們業務持續呈現有利的成長。

  • We achieved solid top line growth with $750.3 million in revenue for the quarter, up 12.5% over the third quarter of last year. The company recorded income related to the Provider Relief Fund established by the CARES Act of $4.4 million during the third quarter of '23 and $7.7 million during the third quarter of 2022. Excluding income from the PRF for both periods, adjusted EBITDA for the third quarter of 2023 increased 13.4% to $175.9 million compared with $155.1 million for the third quarter of 2022.

    本季我們實現穩健的營收成長,季度營收為7.503億美元,較去年第三季成長12.5%。公司於2023年第三季認列《CARES法案》所設立之醫療提供者紓困基金(Provider Relief Fund,PRF)相關收入440萬美元,2022年第三季則為770萬美元。若排除兩期間的PRF收入,2023年第三季調整後EBITDA較2022年第三季的1.551億美元成長13.4%,至1.759億美元。

  • Adjusted income attributable to Acadia's stockholder per diluted share was $0.91, up 13.8% for the third quarter of 2023 compared with $0.80 per diluted share for the third quarter of 2022. Adjustments to income for the third quarter of '23 include the impact of the cost of legal settlements, transaction-related expenses and the related income tax effects of all items.

    2023年第三季,歸屬於Acadia股東之調整後每股稀釋盈餘為0.91美元,較2022年第三季每股稀釋盈餘0.80美元成長13.8%。2023年第三季對盈餘的調整項目包括法律和解成本、交易相關費用,以及所有項目相關的所得稅影響。

  • During the third quarter, we evaluated our professional liability reserves, including an acceleration of our periodic actuarial review. While we perform this review process each year and adjust our reserves accordingly, the timing is usually during fourth quarter. Given the heightened activity and level of discussions regarding litigation reserves, we believe it was prudent to accelerate that review to the third quarter. As a result, we recorded an adjustment to increased professional and general liability reserves by $5.2 million.

    在第三季期間,我們評估了專業責任準備金,包括加速進行我們定期的精算審查。雖然我們每年都會執行此審查流程並相應調整準備金,但通常是在第四季進行。鑑於訴訟準備金相關活動與討論程度升高,我們認為將該審查提前至第三季是審慎之舉。因此,我們將專業責任及一般責任準備金上調520萬美元。

  • After seeing increases in the last 2 years in the form of reserve adjustments, we are not anticipating a meaningful increase in this line item moving forward. Acadia has maintained a strong financial position, which provides us the flexibility to deploy capital, to support our organic growth strategy as well as fund potential acquisitions and future investments.

    在過去兩年以準備金調整的形式出現增加之後,我們預期未來此項目不會再有顯著增加。Acadia維持強健的財務狀況,使我們能靈活運用資本,以支持我們的有機成長策略,並為潛在併購與未來投資提供資金。

  • As of September 30, 2023, we had $99.6 million in cash and cash equivalents and $520 million available under our $600 million revolving credit facility with a net leverage ratio of approximately 2x.

    截至2023年9月30日,我們持有9,960萬美元的現金及約當現金,並在6億美元的循環信用額度下尚有5.20億美元可用,淨槓桿比率約為2倍。

  • Before turning to our guidance, let me briefly touch on the settlement agreements we described in the 8-K filed earlier this week relating to 3 lawsuits involving the company's former Desert Hills facility. As noted in that 8-K, soon after the settlements are approved by the court, Acadia will pay an aggregate $400 million in exchange for a full release and discharge of all related claims. We believe these settlement agreements are a positive step forward and remove uncertainty and future expense associated with the 3 cases.

    在談到我們的指引之前,讓我簡要說明我們本週稍早提交之8-K中所描述的和解協議,該協議涉及公司先前的Desert Hills機構所牽涉的3起訴訟。如該8-K所述,在法院批准和解後不久,Acadia將支付合計4億美元,以換取對所有相關索賠的全面解除與免責。我們認為這些和解協議是向前邁出的正面一步,並消除與這3起案件相關的不確定性及未來費用。

  • We currently intend to pay the settlement funds from a combination of insurance, cash on hand and existing credit lines and affect the entire settlement amount less any portion covered by insurance to be tax deductible. We look forward to turning all of our attention to the continued execution and delivery of the best possible care for our patients, families and communities we serve. And as you can see from the updates to our guidance, our growth in this respect is strong and is expected to remain so.

    我們目前計畫以保險、手頭現金及既有信用額度的組合來支付和解款項,並使整體和解金額扣除任何由保險承擔的部分後可作為稅務可扣抵項目。我們期待將全部注意力投入於持續執行並提供我們病患、家屬及所服務社區最佳可能的照護。正如你們從我們更新後的指引所見,我們在這方面的成長強勁,且預期將持續如此。

  • In fact, as noted in our press release, we have increased our full year expectations for revenue, which are now expected to be in the range of $2.9 billion to $2.92 billion. We also excluding income from the PRF, adjusted EBITDA is now expected to be in the range of $655 million (sic) [$665 million]to $675 million and adjusted earnings per diluted share are now expected to be in the range of $3.33 to $3.43. Please refer to our press release for all of the metrics.

    事實上,如我們新聞稿所述,我們已上調全年營收預期,目前預計介於29億至29.2億美元之間。此外,若排除PRF收入,調整後EBITDA目前預計介於6.55億美元(原文如此)[6.65億美元]至6.75億美元之間,而調整後每股稀釋盈餘目前預計介於3.33至3.43美元之間。所有指標請參閱我們的新聞稿。

  • As a reminder, the company's guidance does not include the impact of any future acquisitions, divestitures, transaction-related expenses or the recognition of additional provider relief fund income.

    提醒各位,公司指引未包含任何未來併購、資產處分、交易相關費用或額外醫療提供者紓困基金收入的認列影響。

  • With that, operator, we're ready to open the call for questions.

    接下來,接線員,我們準備開放提問。

  • Operator

    Operator

  • (Operator Instructions) At this time, we will take our first question, which will come from Whit Mayo with Leerink Partners.

    (接線員指示)此時我們將進行第一個問題,來自Leerink Partners的Whit Mayo。

  • Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst

    Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst

  • Heather, can I just follow up on the professional liability, the net now -- reserve sounds like this was just accelerating the annual process that you guys undertake in the fourth quarter. But -- can you confirm whether or not there's been any changes in the number of claims, the frequency of the claims, the size of the claims, anything that actuarially would have driven the $5 million increase, which I think is similar to what we saw last year. So I'm just not sure what drove this other than perhaps just strengthening of the reserves. So just any additional context would be helpful.

    Heather,我想追問一下專業責任的部分,目前淨額——準備金聽起來只是把你們通常在第四季進行的年度流程提前。但——你能否確認,索賠件數、索賠頻率、索賠金額是否有任何變化,或在精算上是否有任何因素導致這5百萬美元的增加?我認為這與去年看到的情況相近。所以我不太確定除了可能只是強化準備金之外,還有什麼因素驅動。若能提供更多背景會很有幫助。

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Sure, Whit. I can tell you that we follow the same process that we typically follow and it covers claims across all of our facilities for all years. There is no change to sort of the volume of claims or the way that we've evaluated these. I'm sure you'll remember that we took a similar charge in the fourth quarter of last year, and that was actually larger than the reserve that we just recorded, it was $5.9 million last year that we took in the fourth quarter, and we took $5.2 -- or $5.3 million in this quarter.

    當然,Whit。我可以告訴你,我們遵循的流程與平常一致,涵蓋我們所有機構、所有年度的索賠。索賠量或我們評估方式都沒有改變。我相信你會記得,我們去年第四季也提列了類似費用,而且金額其實比這次更大;去年第四季提列590萬美元,而本季我們提列520萬——或530萬美元。

  • Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst

    Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst

  • Okay. My other question maybe just, Chris, an update. I mean the volumes look pretty strong, broad-based, if you could maybe unpack some of the service lines, whether or not there's one individual that stands out more than the others. And now that you've had some time to sort of unpack Medicaid and redeterminations. Is there anything noticeable to call out? Anything that you've learned? Any color would be helpful.

    好的。我另一個問題可能是,Chris,請更新一下。我是說,量看起來相當強勁、且是廣泛性的;你是否可以拆解一下各服務線,看看是否有某一項特別突出。以及現在你們也有一些時間來消化Medicaid與重新資格認定(redeterminations)的情況,有沒有任何值得特別指出的現象?你們學到了什麼?任何補充說明都很有幫助。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. No, thank you, Whit. I'd say all of our service lines are really seeing strong performance. When you look at acute and specialty, they're both up as well as CTC. RTC is also up, not as much, but I would say primarily the volume growth is driven by acute specialty and CTC. And then I would say, on the redeterminations front, all of the advanced preparation that traces back to really a year ago at this time, we feel like it's really paid off for us, and we are not seeing a significant impact on patient volume or peer mix. And just to remind you that when you look at our lines of business, our acute service line continues to outperform and just has seen no noticeable impact from redetermination.

    是的。謝謝你,Whit。我會說我們所有服務線的表現都很強勁。就急性(acute)與專科(specialty)來看,兩者都在成長,CTC也是。RTC也在成長,只是幅度沒那麼大;但我會說,量的成長主要由急性專科與CTC所帶動。至於重新資格認定方面,所有可追溯到大約一年前所做的超前準備,我們覺得確實為我們帶來成效;我們沒有看到對病患量或付費方組合(payer mix)造成顯著影響。也提醒你,從我們的業務線來看,我們的急性服務線持續優於預期,且未見重新資格認定帶來任何可察覺的影響。

  • Specialty is a little bit different and that it's protected due to these unique county-level backstop funding mechanism that we have for patients in Pennsylvania, which is the state that we have most of our specialty Medicaid volume. And then regarding our RTC business, our experience there just continues to support that our patients are protected because roughly 80% of Medicaid patients are wards of the state, and as a result, they are protected.

    專科則稍有不同,因為我們在賓夕法尼亞州的病患有獨特的郡級(county-level)後盾資金機制(backstop funding mechanism)保護;而賓州正是我們大部分專科Medicaid量所在的州。接著就RTC業務而言,我們的經驗持續支持我們的病患受到保護,因為約80%的Medicaid病患是州政府監護(wards of the state),因此受到保障。

  • So for us, redetermination is really primarily applicable to our CTC service line. And I would say our patients there are continuing with their treatment either through the reinstatement of Medicaid, switching to another payer, accessing state-based exchanges, sometimes moving to self-pay as well.

    因此對我們而言,重新資格認定主要適用於我們的CTC服務線。我會說,那裡的病患仍持續接受治療,方式包括Medicaid恢復資格、轉換至其他付費方、使用州級交易所(state-based exchanges),有時也會轉為自費。

  • So more broadly across the country, now that Oregon, which has been the final state actually started redetermination on October 1, all states have officially launched for redetermination. And we'd say that -- we estimate approximately just under half, about 40% of our patients have now completed redetermination, and we anticipate this process will obviously continue to move into '24.

    更廣泛地看全國,隨著最後一個州——奧勒岡州——已於10月1日開始重新資格認定,所有州都已正式啟動重新資格認定。我們估計目前約略不到一半、約40%的病患已完成重新資格認定,而我們預期這個流程顯然將延續到2024年。

  • So I just think in summary, we continue to be cautiously optimistic that the impacts will continue to be very manageable. It continues to be a major focus for the company. We're tracking it very, very closely. Process continues to vary a little bit by state, CMS came in last year in the summer and encourage a number of states to pause the pace that they were moving. Various patients off the rolls. But overall, we believe the impact is going to be modest, particularly in '23 and our experience to date aligns with this view.

    所以我認為總結來說,我們仍然保持審慎樂觀,認為相關影響將會持續在非常可控的範圍內。這仍然是公司的一項重大重點。我們正在非常、非常密切地追蹤。各州的流程仍略有不同;CMS 去年夏天介入並鼓勵若干州放緩其推進速度,暫停將各類患者自名冊中移除。但整體而言,我們相信影響將是溫和的,特別是在 2023 年,而我們迄今為止的經驗也與此觀點一致。

  • Operator

    Operator

  • Our next question will come from A.J. Rice with UBS.

    下一個問題來自 UBS 的 A.J. Rice。

  • Albert J. William Rice - Analyst

    Albert J. William Rice - Analyst

  • I know earlier in the year, there was some concern expressed about whether the payment rates when you gave your original guidance that you were seeing sort of across the board will maybe moderate in the back half of the year, but that seems like that's held in there pretty well. I wondered if I could get you -- for the first question here, just to give us some thoughts about what you're seeing in terms of rate updates and maybe you should look into '24 across your major payer classes?

    我知道今年稍早曾有人擔心,當你們給出最初指引時所看到的、幾乎全面性的支付費率上調,是否會在下半年趨於溫和,但看起來似乎維持得相當不錯。我想先請你們就第一個問題談談:你們在費率更新方面看到什麼情況?以及在你們主要的付款方類別中,對 2024 年應該如何看待?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Sure, A.J., I'll take that question. So first, I'll say, you're right, we are pleased with what we're seeing from a rate perspective. You'll recall, of course, that we sort of increased our guidance midyear based partly on the strength that we were seeing in our rate negotiations. And we were anticipating mid-single-digit growth rates for the second half of the year. And I can tell you that we are seeing that. We are seeing that come through. We've seen it in the third quarter, as you can see sort of in the strong results that we had. And then we are expecting to continue to see those strong rates come through for Q4.

    當然,A.J.,我來回答這個問題。首先我會說,你說得對,我們對目前從費率角度所看到的情況感到滿意。你會記得,當然,我們在年中部分基於費率談判所見到的強勁表現而上調了指引。我們原先預期下半年會有中個位數的成長率。我可以告訴你,我們確實正在看到這一點,正在反映出來。我們在第三季已經看到了,正如你從我們強勁的業績中所見。而我們也預期在第四季會持續看到這些強勁的費率反映出來。

  • I can tell you that, that has been pretty consistent across the markets and across the payers, Medicaid and commercial. And we see the average rate increases in those ranges, of course, there are some above and some below but it's just across all service lines, including CTC. We would expect that to continue into Q1 as we enter 2024. But then we would think that, that's going to moderate back to normal -- more normalized growth levels for 2024.

    我可以告訴你,這在各市場與各付款方之間都相當一致,包括 Medicaid 與商業保險。我們看到的平均費率調升大致落在那些區間;當然有些高一些、有些低一些,但整體涵蓋所有服務線,包括 CTC。我們預期在進入 2024 年時,這樣的趨勢會延續到第一季。但接著我們認為,2024 年將會回落、趨於正常化——回到較為常態的成長水準。

  • Albert J. William Rice - Analyst

    Albert J. William Rice - Analyst

  • No, no, that's fine. I wanted to hear the last part, too, so that's good. My other question would be related to the paid to joint ventures deal, you've obviously announced a lot of deals with major health systems, and it seems to continue to be there. I think there was a perception maybe that some of this was a reaction to these health system challenges in the pandemic and the need to partner up with someone for some of the post-acute services. But I wonder if the discussion that you're seeing now suggest that maybe this is going to persist for longer, would maybe give us a little bit of flavor for what are good discussions with some of these newer JVs that you're seeing? Is it -- what's driving the continued discussion to partner with someone like you to help them on behavioral?

    不,不,這樣很好。我也想聽最後那一段,所以很不錯。我另一個問題與你們的合資(JV)交易有關。你們顯然已經宣布了許多與大型醫療體系的合作案,而且看起來仍在持續。我想外界可能認為其中一部分是因應疫情期間醫療體系面臨的挑戰,以及在後急性照護服務上需要與他人結盟。但我想問的是,你們現在看到的討論是否顯示這種趨勢可能會持續更久?能否請你們分享一些你們與這些較新的合資案之間良好討論的情況?是什麼在驅動他們持續想與像你們這樣的夥伴合作,來協助他們在行為健康(behavioral)方面?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. Thanks, A.J. This is Chris. I'll start and see if Heather wants to add anything. But I think it starts with the fact that we have really impressive referenceability. We have 20 joint ventures that we've now signed. And we had a groundbreaking earlier this week. And just in talking to that partner, I think we continue to see that they're getting calls as listed from others that are interested in some sort of partnership.

    是的,謝謝你,A.J.。我是 Chris。我先回答,看看 Heather 是否要補充。我認為首先在於我們具有非常令人印象深刻的可參考性(referenceability)。我們現在已經簽下 20 個合資案。本週稍早我們也舉行了動土儀式。就我與那位合作夥伴的交流來看,我們仍然看到他們接到其他人打來的電話,表示對某種形式的合作有興趣。

  • I think there's a recognition that there are so many behavioral health patients that present in an emergency room that they would like to get dedicated care and they recognize increasingly that they don't have that expertise. And so they frequently are looking for a partner that can help them deliver care and frequently they just do not have the related beds.

    我認為大家已經意識到,有非常多行為健康患者會出現在急診室,他們希望能提供更專門的照護,也越來越認知到自己並不具備那樣的專業能力。因此他們經常在尋找能協助他們提供照護的合作夥伴,而且他們往往也沒有相應的床位。

  • So I think this is a theme that we've seen. Really began before the pandemic, but I think has accelerated. And I think as we've continued to align ourselves with such marquee partners, that referenceability has continued to persist. And I think our pipeline continues to look very good. Obviously, we continue to do significant work on identifying the target geographies that we feel are underbedded and that starts there.

    所以我認為這是我們看到的一個主題。其實在疫情之前就已經開始,但我認為已經加速。並且隨著我們持續與這些指標性(marquee)的合作夥伴對齊,這種可參考性也持續存在。我認為我們的案源管線看起來仍然非常好。顯然,我們持續投入大量工作來辨識我們認為床位不足(underbedded)的目標地理區域,而這是起點。

  • But where there is a partner that presents themselves in that market or that we proactively approach, joint ventures can be a really attractive growth pathway for us and one that will continue to be a significant part of our growth. And as I laid out in my opening remarks in 2024, it really gives us the visibility into 2024 bed growth that we laid out in our Investor Day.

    但在某個市場中若有合作夥伴主動出現,或是我們主動接觸,合資對我們而言可以是一條非常有吸引力的成長路徑,而且未來也將持續是我們成長的重要組成。如同我在開場談話中所說,到了 2024 年,這也讓我們對 2024 年床位成長有了能見度,正如我們在投資人日所闡述的。

  • Operator

    Operator

  • The next question will come from Kevin Fischbeck with Bank of America.

    下一個問題來自美國銀行(Bank of America)的 Kevin Fischbeck。

  • Kevin Mark Fischbeck - MD in Equity Research

    Kevin Mark Fischbeck - MD in Equity Research

  • Great. I guess last night, CMS finalized the hospital outpatient update. And it included a bunch of things on behavioral health and allowing providers to set up these partial hospitalization programs and things like that. Is that something that you guys would directly participate in? Or is that something that would potentially be increasing competition for the services that you provide?

    很好。我想昨晚 CMS 最終敲定了醫院門診的更新,其中包含許多關於行為健康的內容,並允許提供者設立部分住院計畫(partial hospitalization programs)之類的項目。這是你們會直接參與的事情嗎?還是這可能會增加你們所提供服務的競爭?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Kevin, this is Chris. Thanks for the question. I would say on the PHP IOP front, there is not as much opportunity for us with Medicare specifically. I think the rate increases would certainly apply to us, but we see them as relatively negligible and not a material impact on the business and pretty much in line with what we had expected.

    Kevin,我是 Chris。謝謝你的問題。我會說在 PHP、IOP 這一塊,就 Medicare 而言,我們的機會沒有那麼大。我認為費率上調當然也會適用於我們,但我們認為其影響相對可忽略,對業務不具重大影響,而且基本上符合我們原先的預期。

  • Kevin Mark Fischbeck - MD in Equity Research

    Kevin Mark Fischbeck - MD in Equity Research

  • Okay. And then the revenue growth is pretty impressive. And obviously, EBITDA grew faster, and I appreciate the $5 million charge in the quarter, but I would have thought that with rates growing faster than wages in the quarter and then really strong volume growth, there might be more leverage to the margin in the quarter. Is there anything that you would spike out there or anything that you would highlight there as to why there might not have been more leverage in the quarter on the EBITDA side?

    好的。接著營收成長相當亮眼,而 EBITDA 成長更快;我也理解本季有 500 萬美元的費用,但我原本以為在本季費率成長快於薪資、再加上量能成長很強的情況下,利潤率在本季應該會有更大的槓桿效應。你們是否能指出任何因素,或強調一下為什麼本季在 EBITDA 端沒有出現更多的槓桿?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • I would really point to the point that you just made in regards to that PLGL reserve adjustment, we did see favorable rate increases and we did see sort of labor rates moderating. So you're right on both of those fronts. It's just really that reserve increase that we took in Q3 this year instead of our normal Q4 cadence. But all other things aside, we're progressing well on the other fronts that you mentioned.

    我會回到你剛剛提到的那一點,也就是 PLGL 準備金調整。我們確實看到有利的費率上調,也確實看到勞動力費率有所趨緩,所以你在這兩方面都說得對。主要就是我們今年第三季提列了那筆準備金增加,而不是依照我們通常在第四季進行的節奏。但撇開這些不談,我們在你提到的其他面向都進展良好。

  • Operator

    Operator

  • Our next question will come from Ben Hendrix with RBC.

    下一個問題來自 RBC 的 Ben Hendrix。

  • Benjamin Hendrix - Assistant VP

    Benjamin Hendrix - Assistant VP

  • I wanted to get a little bit more detail on the labor front. The periodic labor screen that we run has also suggested you've made good progress filling open clinical positions over the last few months. And I wanted to get your comments on where you're seeing the strongest hiring activity across the business lines and if there are still areas or geographies where you're seeing capacity constraints? And then finally, what you're expecting for wage inflation next year?

    我想在勞動力方面再多了解一些細節。我們定期進行的勞動力調查也顯示,過去幾個月你們在填補臨床職缺方面取得了不錯的進展。我想請你們評論一下,在各業務線中你們看到招募活動最強勁的是哪些領域?以及是否仍有某些領域或地理區域存在產能限制?最後,你們對明年的薪資通膨有何預期?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Well, I'll start maybe with wage inflation and what we're expecting for next year. I mean, as you know, we've gone from 7.5% to 6.3% to 5.7% ultimately in Q3, and that's starting from Q4 last year at 8.2%. So we've made some significant progress there. We're really happy with that progress, and we definitely expect to see continued progress.

    好,我先從薪資通膨以及我們對明年的預期談起。你也知道,我們已經從 7.5% 降到 6.3%,到第三季最終降到 5.7%,而這是從去年第四季的 8.2% 開始算起。所以我們在這方面取得了相當顯著的進展。我們對這個進展非常滿意,也確實預期會持續看到進一步的改善。

  • We continue to think that we have a path to see further reductions on the actions that we're taking on our part, and Chris can talk about some of your specific hiring questions that you're alluding to in a minute. But those are the actions we're taking, and we feel really good about those things that we're doing. But we remain a little bit cautious in regards to the macroeconomic environment and things that are outside of our control.

    我們仍然認為,透過我們正在採取的行動,我們有路徑可以看到進一步下降;Chris 等一下也可以談談你所提到的一些具體招募問題。但這些就是我們正在做的事情,我們對自己正在做的這些事感覺非常良好。不過,對於總體經濟環境以及一些我們無法控制的外部因素,我們仍然保持一點審慎。

  • I mean, overall, as we just talked about labor inflation, we think will move in tandem with the overall inflation rates and that will ultimately continue to support our reimbursement rate trends. And so we expect that labor inflation will moderate, and it will come more in line with other market trends. But it's a little too early to really put out a number for the guide. We'll come back in February next year with something more solid there, but we expect to continue to make progress.

    我的意思是,整體而言,正如我們剛才談到的勞動力通膨,我們認為它將與整體通膨率同步變動,而這最終將持續支撐我們的報銷費率趨勢。因此,我們預期勞動力通膨將會趨緩,並且會更貼近其他市場趨勢。但現在要真正給出指引數字還有點太早。我們會在明年二月帶著更扎實的內容再回來更新,不過我們預期將持續取得進展。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. And a couple of things that I would add. I would say that we have been very successful in increasing our net new hires and seeing a decline in the open roles that you were referencing, a number of strategies that we've put in place there and a number of actions that I think have really helped drive a reduction in turnover.

    是的。我想再補充幾點。我會說,我們在提高淨新增聘僱方面非常成功,也看到你所提到的職缺數量下降;我們在那裡採取了多項策略,也採取了多項行動,我認為這些確實有助於推動離職率下降。

  • I referenced in the prepared remarks, employee engagement. We did our first employee engagement survey and it's first in the history of the company last year, and we recently did a pulse check to just check on the progress that we're making, and we saw a pretty significant improvement over the baseline in only a short period of time. So we feel really good about the progress that we're making there.

    我在事先準備的發言中提到員工敬業度。我們去年進行了第一次員工敬業度調查,這也是公司史上第一次;而我們最近做了一次脈搏式追蹤(pulse check),只是為了檢視我們所取得的進展,我們在很短的時間內就看到相較基準值有相當顯著的改善。因此,我們對那裡的進展感到非常振奮。

  • I think the other factor that has really helped us with clinical positions, particularly the impact of turnover for RNs and LPNs has been being much more intentional about training and onboarding new employees. I think historically, as a company that has grown by acquisition, we've been very differential to the facilities to put their own training programs in place and by systematizing the way that we do training, we've seen a pretty meaningful reduction in the turnover of clinical employees because we're managing our expectations better upfront.

    我認為另一個對臨床職位很有幫助的因素,特別是對註冊護理師(RN)與實用護理師(LPN)離職影響的改善,是我們在新進員工訓練與到職導入(onboarding)上更有意識、更有系統。我認為過去作為一家透過併購成長的公司,我們在很大程度上讓各據點自行建立訓練計畫;而當我們把訓練方式系統化之後,我們看到臨床員工的離職率有相當明顯的下降,因為我們在一開始就更好地管理了彼此的期待。

  • And I think while this -- we saw this with both RNs and LPNs. LPNs where we saw the most impressive improvement overall. So we continue to focus significantly on 90-day turnover across the board across all lines of business and continue to work very closely with our operators as well as our HR team.

    而我認為,這一點在RN與LPN身上都有看到;其中LPN的整體改善最為顯著。因此,我們持續把重點放在各事業線全面的90天離職率,並且持續與營運團隊以及人資團隊密切合作。

  • And just the final part of your question in terms of, yes, there certainly are some geographies where we continue to see more challenges than others. There are some that are obviously more advantageous. But I think we are doing a much better job as a company in the last year of having that very close working relationship within our HR department being much more closely aligned with our operators. Thanks for the question.

    至於你問題的最後一部分,是的,確實有一些地區我們仍然比其他地區面臨更多挑戰;也有一些地區顯然更有利。但我認為,過去一年我們公司在這方面做得更好:我們的人資部門與營運團隊之間建立了非常緊密的合作關係,並且更加一致協同。謝謝你的提問。

  • Operator

    Operator

  • And our next question will come from Brian Tanquilut with Jefferies.

    下一個問題來自Jefferies的Brian Tanquilut。

  • Brian Gil Tanquilut - Senior Equity/Stock Analyst

    Brian Gil Tanquilut - Senior Equity/Stock Analyst

  • Heather, maybe just clarification on some of the comments you've already made. So if I'm looking at SWB maybe on a per patient day basis, should we think that as something as a KPI that will moderate in terms of growth rate going forward or maybe just track the rate growth number?

    Heather,或許想釐清一下你先前已經提到的一些評論。所以如果我看SWB,可能以每病人日(per patient day)為基礎,我們是否應該把它視為一個KPI,未來其成長率會趨於溫和?或者只是跟著費率成長的數字走?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Yes. If you think about SWB on a per patient day basis, we have typically tracked that. And we have seen -- we saw in previous years how that was sort of growing. And it was -- it had some other contributions that aren't in the normal sort of day-to-day operations that contribute to it. And that includes -- and includes obviously same-facility wage inflation, but it also has some of the corporate function cost benefits that are included in there and then startup losses and then closures. So it has all those different effects.

    是的。如果你以每病人日來看SWB,我們通常就是這樣追蹤的。我們也看到——在過去幾年,我們看到它是如何成長的。而其中——它包含了一些並非日常營運常態的其他貢獻因素。這些包括——當然包括同院(same-facility)的薪資通膨,但也包含一些納入其中的公司職能成本效益,還有新據點啟動虧損,以及關閉據點的影響。所以它有這些不同的效應。

  • So we started to call out sort of the base wage trends that we're seeing because there was a discrepancy between those 2 because some of the investments that we were making. If you look at what's happening with SWB per patient day, it's starting to come back in line with where we're seeing the other sort of the base wage inflation.

    因此,我們開始特別揭露我們所看到的基礎薪資趨勢,因為由於我們所做的一些投資,這兩者之間曾出現落差。如果你看SWB每病人日的變化,它正開始回到與我們看到的其他基礎薪資通膨更一致的水準。

  • SWB as a percentage of revenue actually came down about [60] basis points during the quarter. It came down to 6.3% from 7.5%, and that, of course, continues the decline from the prior year. But you can see that's coming more in line with what you're seeing from a base wage perspective as well. And then on a same facility basis, it decreased by 60 basis points.

    本季SWB占營收比重實際下降了約[60]個基點,從7.5%降至6.3%,而這當然延續了相較前一年的下降趨勢。但你可以看到,這也更貼近你從基礎薪資角度所看到的情況。另外,在同院基礎上,它也下降了60個基點。

  • Brian Gil Tanquilut - Senior Equity/Stock Analyst

    Brian Gil Tanquilut - Senior Equity/Stock Analyst

  • Chris, I guess my second question. As I think about your plan to open about 1,000 beds next year and 1,000 beds in '25. Are you seeing any changes in terms of the construction costs or the speed to start as we see just the macro stuff when construction kind of having an impact on maybe commercial construction as it relates to you guys as well?

    Chris,我想我的第二個問題是。當我思考你們明年計畫開出約1,000張床位、以及在'25年再開出1,000張床位時,隨著我們看到一些總體環境因素、建築業對商用建築可能產生影響,你們是否看到施工成本或啟動速度方面有任何變化,這也可能與你們相關?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. No, thank you. That's a fair question. And I think we've done a really good job overall working through this. I mean we saw a spike in construction costs earlier last year. And it's something that we're constantly having to work through. I think this is one where, particularly with joint venture partners, it's helpful having a partner in the local market.

    是的。不,謝謝。這是個合理的問題。我認為整體而言,我們在處理這件事上做得相當好。我的意思是,我們在去年較早時看到施工成本出現一波上升,而這也是我們必須持續面對並處理的事情。我認為在這方面,特別是與合資(JV)夥伴合作時,在當地市場有一位合作夥伴會很有幫助。

  • So I think we've got a number of strategies in place that we even talked about at our Investor Day with some of the prefabricated construction, some of the things that we're trying to do to get ahead of supply chain constraints for materials that are more difficult to procure. So I would say that overall, we've gotten increasingly better at managing it. It's certainly better than it was a year ago but we're continuing to work through it consistently and our continuous -- continue to be very optimistic with all of the continued growth into 2024 that we have -- that I talked about in my prepared remarks, both on the JV side as well as the de novo side for all of our business lines.

    因此,我認為我們已經採取了多項策略,我們甚至在投資人日也談到過,包括一些預製式建築(prefabricated construction),以及我們為了更難採購的材料而提前因應供應鏈限制所做的一些事情。所以我會說,整體而言,我們在管理這件事上變得越來越好。它確實比一年前好很多,但我們仍在持續、穩定地推進。我們也——對於2024年持續成長仍然非常樂觀,正如我在事先準備的發言中提到的,無論是在合資(JV)端或是新設(de novo)端,涵蓋我們所有的事業線。

  • Operator

    Operator

  • And our next question will come from John Ransom with Raymond James.

    下一個問題來自Raymond James的John Ransom。

  • John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

    John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

  • Just thinking about next year, I know you're not giving guidance, but how should we think about corporate overhead next year over this year, kind of a full year comparison? And also -- do you have a crystal ball on labor inflation? Do you think it's hit a plateau? Or do you think there's some room for it on a patient-day basis to continue to decelerate?

    就明年來看,我知道你們不提供指引,但我們應該如何看待明年的公司管理費用(corporate overhead)相較今年的變化,做一個全年對全年(full year)的比較?另外——你們對勞動力通膨有水晶球嗎?你們認為它已經到達平台期了嗎?還是你們認為以每病人日為基礎,它仍有空間繼續減速?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • John, it's Heather. I'll take that. And I do not have a crystal ball. I wish I did. I can tell you -- so just to go back on a couple of things that we said, we are really pleased with what we're seeing happening from quarter-to-quarter and that continued steady decline in the base wage rates. And then also the base wage rates coming in line with what we're seeing on an SWB per patient day. So those coming in line together and as we start to lap some higher rates in the prior years, we feel good about where we are.

    John,我是Heather。我來回答。我沒有水晶球,我希望我有。我可以告訴你——回到我們剛才提到的幾點,我們對於看到的季度對季度變化感到非常滿意,基礎薪資率持續穩定下降。另外,基礎薪資率也逐步與我們在SWB每病人日所看到的趨勢一致。因此,當這些趨勢逐漸對齊,且我們開始跨越(lap)前幾年較高的薪資水準時,我們對目前的狀況感到樂觀。

  • I mean, we continue to think that we'll see declines and we'll see some improvement until we get to a more normalized rate of inflation, I think our question is, what's the normalized rate of inflation? That inflation is going to continue to move with overall inflation. And the thing that we feel good about, John, is that we can anticipate. The rate improvements will also typically follow that. So we feel like all of those things are going to move in tandem, and we've seen our ability to grow rates at a stronger pace than what we're seeing in our labor inflation so that we can continue to sort of build some operating leverage there.

    我的意思是,我們仍然認為在回到較正常化的通膨水準之前,會看到下降並持續改善;我想我們的問題是,什麼才是正常化的通膨率?通膨將會持續與整體通膨同步變動。而我們覺得有把握的一點,John,是我們可以預期報銷費率的改善通常也會跟著走。所以我們覺得這些因素會同步移動,而且我們也看到,我們提升費率的速度強於我們所看到的勞動力通膨,讓我們能夠持續在那裡建立一些營運槓桿。

  • Kind of coming back to your corporate cost question, what I can tell you is that we're seeing those corporate costs level off. As you know, they sort of built in the prior year and sort of throughout earlier portions of this year but we are seeing those come down slightly. And we're seeing those start to build leverage as a percentage of revenue. I would anticipate that leverage certainly to continue in 2024. It's a little early for us to have sort of a good guide for 2024, for the full year, as you mentioned. But I can tell you that we certainly expect to see that continue in light of leverage that will come there.

    回到你關於公司成本的問題,我可以告訴你的是,我們看到這些公司成本正在趨於持平。如你所知,它們在前一年以及今年較早的期間有所上升,但我們確實看到它們略有下降。我們也看到,作為營收百分比,它們開始產生槓桿效益。我預期這種槓桿效益在2024年肯定會持續。正如你提到的,現在要給出2024年全年一個好的指引還有點早。但我可以告訴你,我們確實預期在這方面會持續看到槓桿帶來的改善。

  • As you know, we made some significant investments in the corporate costs in the past 12 months, and we're seeing those pay off. And we're seeing those pay off in really good ways throughout the business, but also we're seeing corporate costs level off.

    如你所知,我們在過去 12 個月對公司層級成本進行了一些重大投資,而我們正看到這些投資開始回收成效。而且這些成效在整個業務中以非常好的方式展現出來,同時我們也看到公司成本趨於持平。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. And John, this is Chris. I would just add that I think there is direct correlation between the investments that we've made and the performance of the business, whether it's on the marketing side and the record admissions that we're seeing, whether it's the quality investments that we've made that have consistently shown improved quality, even investments in our managed care team and others. So I think this is one where we obviously continue to be very focused on corporate costs and getting operating leverage into Heather's point, that we've seen a sequential decline quarter-over-quarter since the beginning of the year and expect that to continue.

    是的。John,我是 Chris。我想補充的是,我認為我們所做的投資與業務表現之間存在直接關聯,無論是在行銷端以及我們看到的創紀錄入院量,或是我們在品質方面的投資持續展現出品質改善,甚至包括我們對受管醫療團隊及其他方面的投資。因此我認為這是一個我們顯然會持續非常專注於公司成本、並如 Heather 所說導入營運槓桿的領域;自年初以來我們已看到公司成本逐季(quarter-over-quarter)下降,並預期這一趨勢將持續。

  • John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

    John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

  • And just a quick follow-up. The project to digitize your medical records, where does that stand? And are you seeing any payoff from some of the early efforts there?

    再快速追問一下。你們將病歷數位化的專案目前進展到哪一步?你們是否已從一些早期工作中看到任何回報?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. No, thanks for the question on that, John. I think overall, we feel great about the continued progress that we're seeing. There are several elements of the IT investment. So one is the remote monitoring technology that we think has -- we've put that in nearly all of our acute facilities year-to-date. So we're in 45 facilities and we've seen really promising initial improvements in patient incidents there, and we expect that to continue.

    是的。John,謝謝你問到這個問題。我認為整體而言,我們對目前持續看到的進展感到非常振奮。IT 投資有幾個要素。其中之一是遠端監測技術,我們認為這項技術——截至目前我們已在幾乎所有急性照護機構導入。因此我們目前在 45 家機構部署,並已看到病患事件(patient incidents)方面相當令人鼓舞的初步改善,我們也預期這會持續。

  • On the EMR front, we have implemented an EMR now and we're expecting to end the year at about half of our acute facilities and continuing to now deploy -- look at our specialty facilities as well and CTC as well from that standpoint. I think the benefits just show up in a number of different ways. I mean, we've gotten really strong praise from our surveyors who have come into these most recent JVs that we've opened that speak to the strength of the EMR that we have in place and the patient monitoring and how unique and differentiated they see relative to the other surveys that we're doing, we hear that consistently.

    在 EMR(電子病歷)方面,我們現在已完成 EMR 的導入,並預期年底時約有一半的急性照護機構會完成部署;同時也開始持續推進——從這個角度來看,也會評估我們的專科機構以及 CTC。至於效益,我認為會以多種不同方式呈現。我的意思是,我們從前來這些近期新開設 JV(合資機構)的稽核人員那裡獲得非常強烈的讚許,他們談到我們所部署 EMR 的強度,以及病患監測的配置,並且他們認為相較於他們做過的其他稽核,這些做法非常獨特且具差異化;我們也持續一致地聽到這樣的回饋。

  • Again, I think the material improvements that we continue to see on the quality front and only a short period of time also speaks to the benefit we're seeing with patient safety and compliance, which we think is really important. I would say staff engagement, we've seen better employee engagement at facilities that have an EMR relative to those that don't. It's easier to recruit clinicians that have been trained on EMRs that don't want to work in a paper environment, which is consistently the norm in behavioral health. And it helps us on the retention front as well.

    再者,我認為我們在品質面持續看到的實質改善,而且是在很短的時間內,也反映出我們在病患安全與法遵(compliance)方面所看到的效益,而我們認為這非常重要。我也會提到員工投入度(staff engagement):在有導入 EMR 的機構,我們看到員工投入度優於未導入者。對於受過 EMR 訓練、且不想在紙本環境工作的臨床人員而言,招募也更容易;而在行為健康領域,紙本作業一直是常態。這也同樣有助於我們在留任(retention)方面的表現。

  • And then obviously, we're beginning to see the benefits that you would expect just an improved back office functionality, reduce paper and efficiencies there that we think will continue to be much more pronounced in the coming months and we're tracking all of that and expect to be in a position to share probably more detail on that. It will take a little bit more time later next year, certainly by our Investor Day.

    然後很明顯地,我們也開始看到你所預期的效益:後勤(back office)功能更完善、減少紙本,以及相關效率提升;我們認為這些效益在未來幾個月會更加明顯。我們正在追蹤所有這些指標,並預期應該能在之後分享更多細節。這可能還需要一點時間,可能要到明年稍晚,當然在我們的投資人日(Investor Day)之前應該可以。

  • Operator

    Operator

  • And our next question will come from Sarah James with Cantor Fitzgerald.

    下一個問題將由 Cantor Fitzgerald 的 Sarah James 提出。

  • Sarah Elizabeth James - Research Analyst

    Sarah Elizabeth James - Research Analyst

  • I wanted to go back to your comments on the redetermination impact being modest because it seems a little bit of a contrast to what the payers are saying, which is they're getting like 20% to 25% returning to insurance with a 60- to 90-day gap in care. So I'm wondering if you were -- if your patients being returned to some form of insurance, like a geographic mix and given your exposure in Florida or if you're actually able to take an active role and help them resubmit for coverage and close that gap in care?

    我想回到你們對重新認定(redetermination)影響不大的評論,因為這似乎與付款方(payers)的說法有些對比;他們表示大約有 20% 到 25% 的人會回到保險體系,但中間會有 60 到 90 天的照護空窗期。因此我想問的是:你們的病患是否回到某種形式的保險(例如因地理組合、以及你們在佛羅里達的曝險所致)?或者你們其實能夠更主動介入,協助他們重新提交以取得保障,並縮短那段照護空窗期?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. No, thank you for the question, Sarah. I mean it's difficult to know the comparison with respect to others in their geographies. But again, as I started, we have extensively prepared for redetermination, particularly with our CTC business, where it's most pronounced. And I just think we've been able to do an excellent job of proactively working with these patients. I mean we put kiosks in place in the individual facilities.

    是的。Sarah,謝謝你的問題。我的意思是,就其他人在其地理區域的情況而言,很難直接比較。不過如我一開始所說,我們已為重新認定做了非常充分的準備,特別是在我們的 CTC 業務上,因為那裡的影響最為明顯。我認為我們能夠非常出色地主動與這些病患合作。我的意思是,我們在各個機構都設置了自助服務機(kiosks)。

  • We've had QR codes up in place to tell them that redetermination is coming. Many of them come into our clinics on a daily basis with a letter where they've been -- they've lost their Medicaid coverage and they're looking for help. We have a dedicated support line that helps people sometimes will have -- many in our facilities I've seen will sit down with the patient that's lost coverage and take them through actually reapplying in person.

    我們也張貼了 QR code,提醒他們重新認定即將到來。許多人每天到我們診所時都會帶著一封信,內容是——他們已失去 Medicaid(醫療補助)保障,並尋求協助。我們設有專門的支援專線來協助民眾;在我們的許多機構,我也看到有人會坐下來與失去保障的病患一起,實際面對面帶著他們重新申請。

  • Other times, it takes a little bit longer, but we've had a high success rate of being able to assist our patients particularly our CTC patients but also our other lines of business to retain their coverage. And I think in the -- there are many instances as well where we're able to help them get retro coverage where they've lost coverage for a period of time as well. So I would say a very high majority of our patients who have lost coverage have been able to favorably resolved within 30 days. And we just continue to have a really strong track record and continue to expect that to be the case into 2024 as well.

    有時候流程會花更久一點,但我們在協助病患——特別是 CTC 病患、同時也包括其他業務線的病患——維持其保障方面,成功率一直很高。我認為也有許多情況是,我們能協助他們取得追溯性保障(retro coverage),涵蓋他們曾經失去保障的一段期間。因此我會說,我們絕大多數失去保障的病患都能在 30 天內得到有利的解決。我們持續維持非常強的紀錄,也預期在 2024 年仍會如此。

  • Sarah Elizabeth James - Research Analyst

    Sarah Elizabeth James - Research Analyst

  • That's great. And then on the opioid settlement money, you've previously talked about views of it coming down to the county level in '24 and '25. Can you give us an idea of time line once it gets to the county level, how long does it take to get through a grant process? And when could we actually see that having an impact on build-out decisions?

    很好。接著關於阿片類(opioid)和解金,你們先前談到你們認為在 24 年與 25 年會下放到郡(county)層級。你能否讓我們了解一下時間軸:一旦資金到達郡層級,走完補助金(grant)流程通常需要多久?以及我們何時可能真正看到它對擴建(build-out)決策產生影響?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. It's a very fair question and one that we would love to have a more detailed answer to. Every state, as you would expect, is a little bit different. So while there have been $50 billion in opioid settlement dollars in total, only about $3 billion have been distributed to the states. And then once it gets to the states, only a small portion is beginning to trickle down to the individual counties. So we're doing everything that we can to partner with these individual counties with communities to help showcase some of the things that we've seen, some of the strategies to specifically deal with opioid addiction.

    是的。這是非常合理的問題,也是我們很希望能有更細緻答案的一題。每個州如你所預期都略有不同。因此,雖然阿片類和解金總額約 500 億美元,但目前只有約 30 億美元已分配給各州。而當資金到達各州後,只有一小部分才開始逐步下放到各個郡。因此我們正盡一切努力與各個郡及其社區合作,協助展示我們所看到的一些成果,以及一些專門應對阿片類成癮的策略。

  • We partnered with the University of North Carolina to do an independent study on that, that is available for every single county across the country. And we've been able to help show outcomes with respect to harm reduction, treatment efforts that are in place, all the many things that we've done. We have such strong quality metrics that have been recognized by CARF, which is the accrediting body for the CTC that we were able to also talk about and share. But overall, we're doing our best to partner with these counties when they're ready.

    我們與北卡羅來納大學合作進行了一項獨立研究,該研究可供全美每一個郡使用。我們也能協助展示在減害(harm reduction)、既有治療措施等方面的成果,以及我們所做的許多工作。我們有非常強的品質指標,並已獲 CARF(CTC 的認證機構)認可,這些我們也能加以說明與分享。但整體而言,我們會在這些郡準備好時,盡最大努力與他們合作。

  • I just think realistically, they're putting together task force at the county level. They're trying to determine what services they want if it's a rural county do they want access to mobile vans. Do they want to expand pure recovery specialist programs. Do they want housing support? Do they want to just emphasize the distribution of naloxone. I mean it just -- it can really vary county by county. But I think we're there and ready to be a good partner, and we have built a very strong team that is laser-focused on grants and responding to grants that I think we continue to have significant confidence that as these dollars do begin to flow into '24 and certainly into '25, where we probably think that there will be a greater prevalence of that funding that we're very well positioned to capitalize on it and to assist these states.

    我認為更務實地說,他們正在郡層級組成工作小組(task force)。他們試圖決定想要哪些服務:如果是偏鄉郡,他們是否希望能使用行動車(mobile vans);是否想擴大同儕復元專員(peer recovery specialist)計畫;是否需要住房支持;是否只想強調納洛酮(naloxone)的發放。我的意思是——這確實會因郡而異。但我認為我們已準備就緒,能成為很好的合作夥伴;而且我們已建立一支非常強的團隊,專注於補助金(grants)以及回應補助申請。我們仍然非常有信心:隨著這些資金在 24 年開始流入、並且在 25 年更明顯(我們可能認為那時這類資金的普及度會更高),我們將處於非常有利的位置來把握機會,並協助這些州。

  • Operator

    Operator

  • And our next question will come from Gary Taylor with Cowen.

    下一個問題將由 Cowen 的 Gary Taylor 提出。

  • Gary Paul Taylor - MD & Senior Equity Research Analyst

    Gary Paul Taylor - MD & Senior Equity Research Analyst

  • Just a couple of questions. Chris, I just wanted to confirm, I think the latest number we've seen for new bed adds next year is 1,150 and given your commentary about all the development. I just wanted to get a sense of was that just illustrative in confirming all the stuff that's coming in for '24? Or is there a reason to think the bed growth could be even higher than that number you showed us before? And then related to that, just Heather, I know last quarter, you talked about generally $15 million to $20 million a year of preopening costs that burden the P&L, but with bed growth maybe going up 70% or so next year, should we think about a commensurate sort of increase in that preopening burden?

    只有幾個問題。Chris,我想確認一下,我認為我們目前看到的明年新增床位數最新數字是 1,150,並且考量你對所有開發案的評論。我想了解一下,那只是用來說明、用以確認所有將在 '24 進來的項目嗎?還是有什麼理由認為床位成長可能會高於你之前給我們看的那個數字?另外相關的問題是,Heather,我知道上季你提到一般每年約有 1,500 萬到 2,000 萬美元的開辦前成本會影響損益表(P&L),但若明年床位成長可能提高約 70% 左右,我們是否應該預期開辦前負擔也會相應增加?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. Thanks, Gary. Why don't I go ahead and start. So just as you're probably referencing the slide that we felt like it was a very important one to lay out at Investor Day that showed the 1,150 bed additions in '24 and '25. And so just I discussed earlier that 3 hospitals that we'll be building in 2024. We've got 6 facilities coming online. So those 3 JV partners, the Henry Ford, the Intermountain and the other JV partner that we haven't disclosed. We expect those to contribute about 440 beds.

    是的。謝謝你,Gary。我先開始回答。你大概是在指我們在投資人日(Investor Day)上認為非常重要、用來說明的一張投影片,該投影片顯示 '24 與 '25 年將新增 1,150 張床位。我先前也提到,2024 年我們將興建 3 家醫院。我們有 6 個設施將上線。因此,那 3 個合資(JV)夥伴——Henry Ford、Intermountain,以及另一個我們尚未揭露的 JV 夥伴——我們預期它們將貢獻約 440 張床位。

  • We also have several de novo hospitals in reference to one in Agave Ridge in Arizona, Madison, Wisconsin and then this one in Tampa. So we're expecting those to contribute about 400 beds. And then obviously, we have discussed in the past the bed addition to the expansions to existing facilities, which have been in the 300 range. So that gets you right to the 1,150. I would say that we are very actively looking at whether we can even expand beyond the 300.

    我們也有數家新設(de novo)醫院,包括亞利桑那州 Agave Ridge 的一間、威斯康辛州 Madison 的一間,還有坦帕這一間。我們預期這些將貢獻約 400 張床位。然後,當然,我們過去也討論過既有設施擴建所帶來的床位增加,約在 300 張左右。加總起來正好就是 1,150。我會說,我們正非常積極地評估是否能把這個 300 的數字再往上提高。

  • I think that is one of the most effective and highest returns in terms of capital deployment because we do own those facilities, we can control the construction process a little bit more. And we've historically focused on around 300 a year, but we think that can be higher in the coming years and so that's something that we're spending time on as well. But hopefully, that helps break that down.

    我認為就資本配置而言,這是最有效、報酬率最高的方式之一,因為那些設施是我們擁有的,我們也能在一定程度上更好地掌控施工流程。我們過去一直把每年約 300 張作為重點,但我們認為未來幾年這個數字可以更高,因此這也是我們正在投入時間研究的方向。希望這樣能把構成拆解清楚。

  • And Heather, do you want to take the other question?

    Heather,你要回答另一個問題嗎?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Sure. Gary, I'll speak a little bit about the start-up costs. At the end of Q3, we were trending at around $16 million, which includes the ramp of the 2 JVs that Chris mentioned. And as we expect to open 2 more de novos by the end of the year, that sort of pace will continue. We'll see a similar level of about $6.5 million is what we think we're going to continue to see in Q4, and that's consistent with Q3.

    好的。Gary,我來談一下開辦成本(start-up costs)。在第三季末,我們的趨勢約在 1,600 萬美元左右,其中包含 Chris 提到的 2 個 JV 的爬坡(ramp)。而且由於我們預期在年底前還會再開出 2 家 de novo,因此這樣的節奏會持續。我們預期第四季大約會持續看到約 650 萬美元的水準,這與第三季一致。

  • So that number of how we trend has already ramped up a little bit in the back half of 2023. We would expect that, that pace would continue for 2024. So maybe to more directly answer your question, Gary, we think it will be relatively consistent with where we are currently, as we have already started to ramp some of that construction and bed openings, but it won't be the same as what we started the year with last year. It's a little higher for '24 and '23 and it's consistent with where we are right now from going rate.

    因此,這個趨勢數字在 2023 年下半年已經略為上升。我們預期 2024 年會以這樣的節奏延續。更直接回答你的問題,Gary,我們認為它會與目前水準相對一致,因為我們已經開始讓部分施工與床位開放進入爬坡期;但它不會像去年年初那樣的起點。相較之下,'24 與 '23 會略高一些,並且與我們目前的現行水準一致。

  • Operator

    Operator

  • And our last question will come from Pito Chickering with Deutsche Bank.

    我們的最後一個問題來自德意志銀行(Deutsche Bank)的 Pito Chickering。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Two quick questions here. One more follow-up on Medicaid redeterminations. As you look at your DSOs pick up slightly sequentially as redetermination has a bigger impact. Can you just say the process for how you learn if a (inaudible) patient has been redetermined? I believe you build CVC weekly. So I assume that you know within 1 or 2 weeks that there's -- if that person's has been redetermined, there's minimal risk of billing revenues that you can't collect?

    這裡兩個簡短問題。第一個是關於 Medicaid 重新認定(redeterminations)的追問。當你們看到隨著重新認定影響加大,你們的 DSO(應收帳款週轉天數)在序列上略有上升。你能否說明一下,你們是如何得知某位(聽不清)病患已被重新認定的流程?我相信你們每週建立 CVC。所以我推測你們在 1 到 2 週內就會知道——如果那個人已被重新認定——那麼對於你們可能無法收回的帳單收入,風險應該很小?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. Thank you, Pito. I would say it continues to really vary state by state. So there are some states that have proactively worked with us, and we'll actually in the beginning of the period where they're moving various patients and citizens off Medicaid, they will share with us proactively when that's going to happen and who is on the roles. And that enables us to cross-reference against our patients and to be much more proactive in reaching out. Other times, that process doesn't happen in our patients even though we have been proactively talking to them about this for some time, will come into us with a hard copy letter that they've received where they've lost their coverage, and we have to work with them.

    是的。謝謝你,Pito。我會說這確實仍然因州而異。有些州會主動與我們合作,在他們開始把不同病患與民眾從 Medicaid 名單中移除的期間,一開始就會主動與我們分享何時會發生、以及名單上有哪些人。這讓我們能與我們的病患名單交叉比對,並更主動地聯繫。其他時候,這個流程並不會發生;即使我們已經主動與病患溝通一段時間,我們的病患仍可能拿著他們收到的紙本通知信來找我們,信上寫著他們已失去保障,我們就必須與他們一起處理。

  • So we've done everything we can to point out the states that have been particularly transparent and shared with others, how that really is in the patient's best interest, but it really varies state by state.

    因此,我們已盡一切努力指出哪些州特別透明、並與其他州分享這樣做其實最符合病患的利益,但整體而言確實是因州而異。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Okay. Fair enough. And then a quick modeling question. If you look at OpEx in the fourth quarter and take out -- sorry, OpEx for the third quarter and take out $5.3 million for professional fees per patient day. Can we assume a similar number for that for fourth quarter, just adjusting for the professional liability?

    好的。可以理解。接著是一個快速的建模問題。如果你看第四季的 OpEx(營運費用),並把——抱歉,是看第三季的 OpEx,並扣除每病患日 530 萬美元的專業費用。我們是否可以假設第四季也會是類似的數字,只需針對專業責任(professional liability)做調整?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • I think that's right. Our other operating expenses have been pretty consistent, right around 13% of revenue. If you take out the impact of the $5.3 million reserve adjustment, we are at 13.2% for Q3. So we're right in line with Q3 prior year, which is 13.3%. And then sequentially, Q2 of 2023 was 13.1%. So to answer your question, yes, you can expect that we'll come right back in line.

    我認為是的。我們的其他營運費用一直相當一致,大約在營收的 13% 左右。如果把 530 萬美元準備金調整(reserve adjustment)的影響拿掉,我們第三季是 13.2%。因此,這與去年同期第三季的 13.3% 非常一致。而就序列而言,2023 年第二季是 13.1%。所以回答你的問題,是的,你可以預期我們會回到相當一致的水準。

  • Operator

    Operator

  • And this concludes our question-and-answer session. I'd like to turn the conference back over to Chris Hunter for any closing remarks.

    以上為我們的問答環節。接下來我想把電話會議交回給 Chris Hunter,請他做任何結語。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Thank you. So before we end the call, I just want to again thank our committed facility leaders, clinicians and approximately 23,000 dedicated employees across the country, who just continued to work tirelessly to meet the needs of patients in a safe and effective manner. We have such a strong foundation and a proven strategy for driving growth and delivering greater value to both the patients we serve and our shareholders.

    謝謝。在結束本次電話會議之前,我想再次感謝我們投入的各院所領導團隊、臨床人員,以及全國約 23,000 名敬業的員工,他們持續不懈地工作,以安全且有效的方式滿足病患需求。我們擁有非常堅實的基礎,以及一套經驗證的策略,能推動成長並為我們服務的病患與股東帶來更高的價值。

  • We greatly thank you all for being with us this morning and for your interest in Acadia. And if you all have additional questions today, please don't hesitate to contact us directly. Have a great day.

    非常感謝各位今天早上與我們同在,並對 Acadia 的關注。如果各位今天還有其他問題,請隨時直接與我們聯繫。祝各位有美好的一天。

  • Operator

    Operator

  • The conference has now concluded. Thank you for attending today's presentation. You may now disconnect your lines.

    本次會議到此結束。感謝各位參加今天的簡報。您現在可以掛斷電話線。